540 related articles for article (PubMed ID: 21781227)
41. Antisense MDM2 enhances the response of androgen insensitive human prostate cancer cells to androgen deprivation in vitro and in vivo.
Mu Z; Hachem P; Hensley H; Stoyanova R; Kwon HW; Hanlon AL; Agrawal S; Pollack A
Prostate; 2008 May; 68(6):599-609. PubMed ID: 18196567
[TBL] [Abstract][Full Text] [Related]
42. Down-regulation of Skp2 is correlated with p27-associated cell cycle arrest induced by phenylacetate in human prostate cancer cells.
Shibahara T; Onishi T; Franco OE; Arima K; Sugimura Y
Anticancer Res; 2005; 25(3B):1881-8. PubMed ID: 16158921
[TBL] [Abstract][Full Text] [Related]
43. Androgen sensitivity related proteins in hormone-sensitive and hormone-insensitive prostate cancer cell lines treated by androgen antagonist bicalutamide.
Madarová J; Lukesová M; Hlobilková A; Riháková P; Murray PG; Student V; Vojtsek B; Kolár Z
Neoplasma; 2001; 48(5):419-24. PubMed ID: 11845989
[TBL] [Abstract][Full Text] [Related]
44. Combination therapy of antiandrogen and XIAP inhibitor for treating advanced prostate cancer.
Danquah M; Duke CB; Patil R; Miller DD; Mahato RI
Pharm Res; 2012 Aug; 29(8):2079-91. PubMed ID: 22451249
[TBL] [Abstract][Full Text] [Related]
45. Genome-wide impact of androgen receptor trapped clone-27 loss on androgen-regulated transcription in prostate cancer cells.
Nwachukwu JC; Mita P; Ruoff R; Ha S; Wang Q; Huang SJ; Taneja SS; Brown M; Gerald WL; Garabedian MJ; Logan SK
Cancer Res; 2009 Apr; 69(7):3140-7. PubMed ID: 19318562
[TBL] [Abstract][Full Text] [Related]
46. Synergistic targeting of PI3K/AKT pathway and androgen receptor axis significantly delays castration-resistant prostate cancer progression in vivo.
Thomas C; Lamoureux F; Crafter C; Davies BR; Beraldi E; Fazli L; Kim S; Thaper D; Gleave ME; Zoubeidi A
Mol Cancer Ther; 2013 Nov; 12(11):2342-55. PubMed ID: 23966621
[TBL] [Abstract][Full Text] [Related]
47. Inhibition of tumor growth and progression of LNCaP prostate cancer cells in athymic mice by androgen and liver X receptor agonist.
Chuu CP; Hiipakka RA; Kokontis JM; Fukuchi J; Chen RY; Liao S
Cancer Res; 2006 Jul; 66(13):6482-6. PubMed ID: 16818617
[TBL] [Abstract][Full Text] [Related]
48. ASC-J9 suppresses castration-resistant prostate cancer growth through degradation of full-length and splice variant androgen receptors.
Yamashita S; Lai KP; Chuang KL; Xu D; Miyamoto H; Tochigi T; Pang ST; Li L; Arai Y; Kung HJ; Yeh S; Chang C
Neoplasia; 2012 Jan; 14(1):74-83. PubMed ID: 22355276
[TBL] [Abstract][Full Text] [Related]
49. Androgen receptor remains critical for cell-cycle progression in androgen-independent CWR22 prostate cancer cells.
Yuan X; Li T; Wang H; Zhang T; Barua M; Borgesi RA; Bubley GJ; Lu ML; Balk SP
Am J Pathol; 2006 Aug; 169(2):682-96. PubMed ID: 16877366
[TBL] [Abstract][Full Text] [Related]
50. Induction of bicalutamide sensitivity in prostate cancer cells by an epigenetic Puralpha-mediated decrease in androgen receptor levels.
Liu X; Gomez-Pinillos A; Liu X; Johnson EM; Ferrari AC
Prostate; 2010 Feb; 70(2):179-89. PubMed ID: 19790234
[TBL] [Abstract][Full Text] [Related]
51. TACC2 is an androgen-responsive cell cycle regulator promoting androgen-mediated and castration-resistant growth of prostate cancer.
Takayama K; Horie-Inoue K; Suzuki T; Urano T; Ikeda K; Fujimura T; Takahashi S; Homma Y; Ouchi Y; Inoue S
Mol Endocrinol; 2012 May; 26(5):748-61. PubMed ID: 22456197
[TBL] [Abstract][Full Text] [Related]
52. Identification of novel androgen receptor target genes in prostate cancer.
Jariwala U; Prescott J; Jia L; Barski A; Pregizer S; Cogan JP; Arasheben A; Tilley WD; Scher HI; Gerald WL; Buchanan G; Coetzee GA; Frenkel B
Mol Cancer; 2007 Jun; 6():39. PubMed ID: 17553165
[TBL] [Abstract][Full Text] [Related]
53. A novel antiandrogen, Compound 30, suppresses castration-resistant and MDV3100-resistant prostate cancer growth in vitro and in vivo.
Kuruma H; Matsumoto H; Shiota M; Bishop J; Lamoureux F; Thomas C; Briere D; Los G; Gleave M; Fanjul A; Zoubeidi A
Mol Cancer Ther; 2013 May; 12(5):567-76. PubMed ID: 23493310
[TBL] [Abstract][Full Text] [Related]
54. A 90 kDa fragment of filamin A promotes Casodex-induced growth inhibition in Casodex-resistant androgen receptor positive C4-2 prostate cancer cells.
Wang Y; Kreisberg JI; Bedolla RG; Mikhailova M; deVere White RW; Ghosh PM
Oncogene; 2007 Sep; 26(41):6061-70. PubMed ID: 17420725
[TBL] [Abstract][Full Text] [Related]
55. Androgen receptor or estrogen receptor-beta blockade alters DHEA-, DHT-, and E(2)-induced proliferation and PSA production in human prostate cancer cells.
Arnold JT; Liu X; Allen JD; Le H; McFann KK; Blackman MR
Prostate; 2007 Aug; 67(11):1152-62. PubMed ID: 17503469
[TBL] [Abstract][Full Text] [Related]
56. Plant-derived 3,3'-Diindolylmethane is a strong androgen antagonist in human prostate cancer cells.
Le HT; Schaldach CM; Firestone GL; Bjeldanes LF
J Biol Chem; 2003 Jun; 278(23):21136-45. PubMed ID: 12665522
[TBL] [Abstract][Full Text] [Related]
57. Nuclear Receptor Corepressor 1 Expression and Output Declines with Prostate Cancer Progression.
Lopez SM; Agoulnik AI; Zhang M; Peterson LE; Suarez E; Gandarillas GA; Frolov A; Li R; Rajapakshe K; Coarfa C; Ittmann MM; Weigel NL; Agoulnik IU
Clin Cancer Res; 2016 Aug; 22(15):3937-49. PubMed ID: 26968201
[TBL] [Abstract][Full Text] [Related]
58. Androgen receptor modifications in prostate cancer cells upon long-termandrogen ablation and antiandrogen treatment.
Marques RB; Erkens-Schulze S; de Ridder CM; Hermans KG; Waltering K; Visakorpi T; Trapman J; Romijn JC; van Weerden WM; Jenster G
Int J Cancer; 2005 Nov; 117(2):221-9. PubMed ID: 15900601
[TBL] [Abstract][Full Text] [Related]
59. A novel selective androgen receptor modulator (SARM) MK-4541 exerts anti-androgenic activity in the prostate cancer xenograft R-3327G and anabolic activity on skeletal muscle mass & function in castrated mice.
Chisamore MJ; Gentile MA; Dillon GM; Baran M; Gambone C; Riley S; Schmidt A; Flores O; Wilkinson H; Alves SE
J Steroid Biochem Mol Biol; 2016 Oct; 163():88-97. PubMed ID: 27106747
[TBL] [Abstract][Full Text] [Related]
60. Effects of treatment with androgen receptor ligands on microRNA expression of prostate cancer cells.
Segal CV; Koufaris C; Powell C; Gooderham NJ
Toxicology; 2015 Jul; 333():45-52. PubMed ID: 25846647
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]